EPTIS
BAM Logo

Myositis Specific and Scleroderma Antibodies

EPTIS factsheet 790791 | Last revision 2020-10-23 | URL: https://www.eptis.bam.de/pts790791 https://www.eptis.bam.de/pts790791

PT provider
PT provider RCPAQAP RCPAQAP
Based in Australia
Language(s) English
Remarks
Keywords
Product groups Human test material
Testing fields Medical analysis
Technical details
Test item Tested property Testing method
Serum Myositis and Scleroderma Antibodies Mi-2
Mi-2a
MI-2b
Ku
RNA Pol III
Cenp
MDA5
NXP2
SAE1
TIF1g
PL-7
OJ
EJ
Jo-1
PM-Scl
others as appropriate
Aims of the PT scheme
Target group of participants
Linked to specific legislation / standards
Additional, subsidiary aims
Number of participants
Accredited or otherwise reviewed by a 3rd party
Operation is commissioned / requested by
Fees and frequency
Participation fee Yes
Regularly operated Yes (1 case per survey/6 surveys)
Year of first operation
Contact details of the PT provider
Provider Contact person
RCPAQAP
Suite 201/8 Herbert Street
St Leonards, 2065
Australia

Phone: (61 2) 9045 6000
Fax: (61 2) 9356 2003
Web: https://www.rcpaqap.com.au/ https://www.rcpaqap.com.au/
Mr Rhys Judd
Phone: (61 2) 9045 6000
Fax: (61 2) 9356 2003
Email: rhys.judd@rcpaqap.com.au rhys.judd@rcpaqap.com.au
If you find any mistakes please contact the responsible EPTIS coordinator in Australia, Ms Luminita Antin. Ms Luminita Antin.
Any questions or problems? Please contact us at eptis@bam.de.
Application version: 1.21